Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease-Reference-Cited by-同舟云学术

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

Published:2012-01 Issue:1 Volume:35 Page:25-29
ISSN:0362-5664
Container-title:Clinical Neuropharmacology
language:en
Short-container-title:

Author:

Uenaka Kazunori,Nakano Masako,Willis Brian A.,Friedrich Stuart,Ferguson-Sells Lisa,Dean Robert A.,Ieiri Ichiro,Siemers Eric R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Reference6 articles.

1. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics.;Hardy;Science,2002

2. . Safety and Changes in plasma and cerebrospinal fluid amyloid A after a single administration of an amyloid A monoclonal antibody in subjects with Alzheimer disease.;Siemers;Clin Neuropharmacol,2010

3. . Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimers Disease.;McKhann;Neurology,1984

4. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician.;Folstein;J Psychiatr Res,1975

5. . Cerebral blood flow in dementia.;Hachinski;Arch Neurol,1975

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial;Neurology and Therapy;2024-04-06

2. Alzheimer’s disease: Systematic review of recent substantial therapeutic targets;AIP Conference Proceedings;2024

3. Passive Immunotherapies Targeting Amyloid-βin Alzheimer’s Disease: A Quantitative Systems Pharmacology Perspective;Molecular Pharmacology;2023-10-31

4. 18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer’s Disease Biomarkers in Subjective Cognitive Decline Population;Journal of Alzheimer's Disease;2023-05-16

5. Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease;Frontiers in Neurology;2023-03-15